SALT
LAKE CITY, Aug. 15, 2024 /PRNewswire/ --
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a
molecular diagnostics company with a unique, patented platform for
the development of molecular diagnostic tests, announced today that
it will be sponsoring, presenting and hosting a booth at the
16th Annual Next Generation Dx Summit, held virtually
and in-person in Washington, D.C.
on August 19-21, 2024.
Cambridge Healthtech Institute's Next Generation Dx Summit is
described as the nexus for international thought leaders to discuss
diagnostic advancement and technology innovation, and offers a
valuable window into how point-of-care, decentralized
testing, infectious disease, liquid biopsy and companion
diagnostics are changing the standard of care.
On Monday, August 19, at
12:15 PM ET, Company CEO Dwight Egan will be presenting on the Company's
forthcoming PCR platform, which is currently under FDA review and
is not currently for sale, in a luncheon presentation titled "Co-Dx
PCR Platform: The Future of Accessible Diagnostics."
Attendees are invited to visit the Company at Booth #26 to learn
more about the upcoming Co-Dx PCR testing platform as well as the
Co-Dx Logix Smart® suite of clinical laboratory solutions. These
solutions include Research Use Only (RUO) tests for mpox** virus,
one of which was included in a study published in the Oxford
Academic journal Open Forum Infectious Diseases in December,
2023. Yesterday, the World Health Organization Director-General
declared mpox a public health emergency of international
concern (PHEIC).
To learn more about the summit, including in-person and virtual
registration details, please visit
https://www.nextgenerationdx.com.
*The Co-Dx PCR platform (including the PCR Home™, PCR Pro™,
mobile app, and all associated tests) is subject to review by the
FDA and/or other regulatory bodies and is not available for sale.
The Co-Dx PCR Pro instrument and Co-Dx COVID-19 Test are currently
under review by the FDA and are not available for sale.
**The Co-Dx Logix Smart® Mpox and Co-Dx Logix Smart® Mpox
2-Gene tests are for Research Use Only. Not for use in diagnostic
procedures.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a
Utah corporation, is a molecular
diagnostics company that develops, manufactures and markets
state-of-the-art diagnostics technologies. The Company's
technologies are utilized for tests that are designed using the
detection and/or analysis of nucleic acid molecules (DNA or RNA).
The Company also uses its proprietary technology to design specific
tests for its Co-Dx PCR at-home and point-of-care platform and to
locate genetic markers for use in applications other than
infectious disease.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-to-present-at-16th-next-generation-dx-summit-in-washington-dc-302223138.html
SOURCE Co-Diagnostics